Shots:

• The P-III LUCENT trial includes LUCENT-1- 2 & 3. The P-III LUCENT-1 induction study involves assessing mirikizumab vs PBO in patients with a mod. to sev. UC who had failed conventional and/or biologic treatments for 12wks.
• The LUCENT-1 study resulted in meeting its 1EPs of clinical remission with all 2EPs. The 2EPs includes a reduction in bowel urgency- clinical response- endoscopic & symptomatic remission- improvement in endoscopic histologic inflammation
• Additionally- Mirikizumab demonstrated improvement in symptoms as early as 4wks. after initiating treatment. The full results of induction and maintenance studies anticipated in H1’22

 ­ Ref: PRNewswire | Image: US News